Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0
|
作者：
Narezkina, Anna [1 ]
Akhter, Nausheen [2 ]
Lu, Xiaoxiao [3 ]
Emond, Bruno [4 ]
Huang, Qing [3 ]
Panjabi, Sumeet [3 ]
Hilts, Annalise [4 ]
Lu, Stephanie [5 ]
Lafeuille, Helene [4 ]
Lafeuille, Marie-Helene [4 ]
Choi, Michael [6 ]
机构：
[1] Univ Calif San Diego Hlth, San Diego, CA USA
[2] Northwestern Med, Chicago, IL USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Anal Grp Inc, Montreal, PQ, Canada
[5] Anal Grp Inc, Menlo Pk, CA USA
[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-390
引用
收藏
页码：S276 / S277
页数：2
相关论文
共 50 条
  • [1] Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
    Narezkina, Anna
    Lu, Xiaoxiao
    Emond, Bruno
    Cote-Sergent, Aurelie
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    BLOOD, 2021, 138
  • [2] Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
    Narezkina, Anna
    Akhter, Nausheen
    Lu, Xiaoxiao
    Emond, Bruno
    Panjabi, Sumeet
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Choi, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (11): : E959 - E971
  • [3] A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Zhu, Huayuan
    Xia, Yi
    Miao, Yi
    Qin, Shuchao
    Wu, Wei
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2023, 142
  • [4] Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shadman, Mazyar
    Salkar, Monika
    Srivastava, Bhavini
    Karve, Sudeep
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Agatep, Barnabie
    Jones, Barton
    Franceschini, Erin
    Saifan, Chadi
    Bacchus, Shaffee
    Roeker, Lindsey
    Stephens, Deborah M.
    LEUKEMIA & LYMPHOMA, 2024,
  • [5] Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Patel, Sima
    Saifan, Chadi
    Salkar, Monika
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Stephens, Deborah M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S327 - S327
  • [6] Real-world duration of venetoclax treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma
    Teschemaker, Anna
    Hakre, Shweta
    Tse, Jenny
    Shaikh, Nazneen Fatima
    Gu, Yifan
    Near, Aimee
    LEUKEMIA & LYMPHOMA, 2023, 64 : S62 - S63
  • [7] Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib
    Jacobs, Ryan
    Wang, Ruibin
    He, Jinghua
    Lu, Xiaoxiao
    Wu, Linda
    Khan, Wasiulla
    Qureshi, Zaina P.
    Levy, Moshe Yair
    BLOOD, 2022, 140 : 8017 - 8018
  • [8] Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Chanan-Khan, Asher Alban
    Challagulla, Swetha
    Donckels, Elizabeth
    Chuang, Po-Ya
    Yang, Keri
    BLOOD, 2023, 142
  • [9] Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation
    Fradley, Michael
    Lafeuille, Marie-Helene
    Emond, Bruno
    Crawford, Samuel
    Chen, Naijun
    Volodarsky, Raisa
    Nielsen, Jacqueline
    Srivastava, Bhavini Patel
    BLOOD, 2022, 140 : 10983 - 10984
  • [10] Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Donzella, Sidney M.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10932 - 10933
12345